切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (03) : 337 -341. doi: 10.3877/cma.j.issn.1674-1358.2016.03.018

临床论著

孕期服用替比夫定进行乙型肝炎母婴阻断的产后肝功能观察
庄虔莹1, 刘敏1, 付冬1, 马小艳2, 蔡晧东2,()   
  1. 1. 100015 北京,首都医科大学附属北京地坛医院妇产科
    2. 100015 北京,首都医科大学附属北京地坛医院肝病科
  • 收稿日期:2015-08-27 出版日期:2016-06-15
  • 通信作者: 蔡晧东

The postpartum changes of liver function after telbivudine treatment in preventing mother-to-child transmission of hepatitis B virus infection during pregnancy

Qianying Zhuang1, Min Liu1, Dong Fu1, Xiaoyan Ma2, Haodong Cai2,()   

  1. 1. Department of Obstetrics and Gynecology, Beijing Ditan Hosipital, Capital Medical University, Beijing 100015, China
    2. Department of Hepatopathy, Beijing Ditan Hosipital, Capital Medical University, Beijing 100015, China
  • Received:2015-08-27 Published:2016-06-15
  • Corresponding author: Haodong Cai
引用本文:

庄虔莹, 刘敏, 付冬, 马小艳, 蔡晧东. 孕期服用替比夫定进行乙型肝炎母婴阻断的产后肝功能观察[J/OL]. 中华实验和临床感染病杂志(电子版), 2016, 10(03): 337-341.

Qianying Zhuang, Min Liu, Dong Fu, Xiaoyan Ma, Haodong Cai. The postpartum changes of liver function after telbivudine treatment in preventing mother-to-child transmission of hepatitis B virus infection during pregnancy[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(03): 337-341.

目的

探讨HBeAg阳性高病毒载量的孕妇在孕期是否服用替比夫定以及产后不同的停药时间对其肝功能的影响。

方法

收集2012年1月至2013年12月于首都医科大学附属北京地坛医院生育的HBeAg阳性高病毒载量的妊娠妇女626例,分为替比夫定组(LdT组,267例)和未用抗病毒药物组(对照组,359例);回顾性分析孕中期服用替比夫定与不服抗病毒药物治疗及不同停药时间的孕妇血清HBV DNA、产后肝功能的变化。

结果

LdT组母亲服用替比夫定后HBV DNA水平显著低于对照组(t = 55.2413,P = 0.0000),LdT组孕妇产前HBV DNA< 500拷贝/ml的例数显著高于对照组(χ2 = 49.5180,P = 0.0000)。两组母亲产后6个月内最高ALT水平差异具有统计学意义(Z =-0.021,P = 0.9836),对照组母亲产后ALT> 2 × ULN的病例数比LdT组多(χ2 = 9.1562,P = 0.002)。产后0~29 d停药的母亲ALT水平和> 2 × ULN的病例数均高于产后> 30 d停药者。

结论

替比夫定用于妊娠第3期加强HBV母婴阻断可以有效降低母亲体内HBV DNA水平,替比夫定治疗未增加产后ALT升高的风险,而产后停药过早可能增加ALT升高的风险。

Objective

To investigate the changes of liver function of woman with higher quantities of antepartum serum HBV who took telbivudine during pregnancy or not and the different withdraw times after delivery.

Methods

Total of 626 HBeAg positive pregnant patients with high viral load of HBV DNA were collected in Beijing Ditan Hospital, Capital Medical University from January 2012 to December 2013. They were divided into two groups: telbivudine treatment group (LdT group, 267 cases) and without antiviral drug group (control group, 359 cases). The levels of serum HBV DNA and the change of liver function were analyzed between women who took telbivudine during pregnancy or not and the different withdraw times after delivery.

Results

The HBV DNA levels in LdT group significantly decreased than that of control group (t = 55.2413, P = 0.0000). The amount of pregnant women with HBV DNA < 500 copies/ml in LdT group was more than those in the control group (χ2 = 49.5180, P = 0.0000). There was no significant difference between the two groups at liver function in the first 6 months after delivery (Z =-0.021, P = 0.9836). The cases with ALT > 2 × ULN of postpartum in control group were more than those in the LdT group (χ2 = 9.1562, P = 0.002). The levels of ALT were higher in women who suspended telbivudine 0-29 days after delivery than those suspended telbivudine more than 30 days after delivery. The number of postpartum women with > 2 × ULN in women who suspended telbivudine 0-29 days after delivery were more than the postpartum women who suspended telbivudine for more than 30 days.

Conclusions

Telbivudine presents an enhanced effect of preventing mother-infant transmission of hepatitis B virus infection during the third pregnancy stage. With the decreasing of HBV DNA level, telbivudine would not attribute to the risk of ALT increasing, while the withdraw in the early stage might relate to higher ALT level.

表1 两组母亲基线时人口学基本情况
表2 两组母亲产前HBV DNA载量
表3 两组母亲产后肝功能比较
表4 LdT组母亲产后停药时间与ALT水平的相关性
1
Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period[J]. Int J Infect Dis,2012,16(2):e82-e88.
2
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南2010年版更新版[J/CD]. 中华实验和临床感染病杂志:电子版,2011,5(1):50-60.
3
Ngui SL, Andrews NJ, Underhill GS, et al. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors[J]. Clin Infect Dis,1998,27(1):100-106.
4
Han L, Zhang HW, Xie JX, et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J]. World J Gastroenterol,2011,17(38):4321-4333.
5
Liu MH, Sheng YJ, Liu JY, et al. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis[J]. Ann Saudi Med,2013,33(2):169-176.
6
Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovirdisoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J]. J Hepatol,2014,61(3):502-507.
7
曾艳梅,张思泉,娄国强, 等. 替比夫定阻断乙型肝炎病毒宫内感染的临床研究[J]. 中国临床药理学与治疗学,2010,15(4):443-445.
8
Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2012,10(5):520-526.
9
张先华. 替比夫定阻断血清HBV高载量孕妇母婴传播的疗效和安全性观察[J]. 实用肝脏病杂志,2015,18(4):411-412.
10
王习习,韩国荣,王翠敏, 等. 替比夫定治疗慢性HBV感染孕妇分娩停药后生化学和病毒学研究[J]. 实用临床医药杂志,2015,19(7):136-138.
11
EASL clinical practice guidelines: management of chronic hepatitis B virus infection[M]. J Hepatol,2012,57(1):167-185.
12
曹彦君,刘敏,蔡晧东, 等. 免疫耐受期HBV感染的孕妇产后肝功能变化[J/CD]. 中华实验和临床感染病杂志:电子版,2013,7(3):444-447.
13
Giles M, Visvanathan K, Lewin S, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J]. Rut,2015,64(11):1810-1815.
14
Tan HH, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy[J]. HepatolInt,2008,2(3):370-375.
15
ter BMJ, Leemans WF, de Man RA, et al. Exacerbation of chronic hepatitis B infection after delivery[J]. J Viral Hepat,2008,15(1):37-41.
16
Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission[J]. Scand J Infect Dis,2003,35(11-12):814-819.
17
Ter Borg MJ, Leemans WF, de Man RA, et al. Exacerbation of chronic hepatitis B infection after delivery[J]. J Viral Hepat,2008,15(1):37-41.
18
Giles ML, Visvanathan K, Lewin SR, et al. Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv,2012,67(1): 37-44.
19
Lin HH, Chen PJ, Chen DS, et al. Postpartum subsidence ofhepatitis B viral replication in HBeAg-positive carrier mothers[J]. J Med Virol,1989,29(1):1-6.
20
姜捷,丁登森,刘国庆. 替比夫定与阿德福韦酯治疗慢性乙型肝炎近期病毒学和生化学应答比较[J]. 山东医药,2010,50(13):47-48.
21
黄鸿菲,何登明,吴全新, 等. HBeag阳性慢性乙型肝炎孕妇替比夫定治疗前后血清Th1/Th2型细胞因子的水平变化[J]. 临床肝胆病杂志,2014,30(6):522-526.
22
Lin HH, Wu WY, Kao JH, et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics[J]. J Gastroenteml Hepatol,2006,21(3):605-609.
23
邓勇,吴维新,张丸志, 等. 替比夫定阻断乙型肝炎病毒母婴传播停药后的安全性研究[J]. 中华肝脏病杂,2015,23(8):586-589.
24
Jonas MM. Hepatitis B and pregnancy: an underestimated issue[J]. Liver Int,2009,29(1):133-139.
25
陈蓉,曾艳梅,张素英, 等. 拉米夫定阻断乙肝病毒宫内感染分娩后不同停药时间对妊娠妇女的影响[J]. 中国现代应用药学,2012,28(4):364-367.
[1] 李钱梅, 何冠南, 赵婧, 陈曦, 唐玉英, 马丽琼, 梁蓉, 袁桃, 李明星. 早孕期低危妊娠和高危妊娠胎盘微血流成像特征及预后分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 726-732.
[2] 张舒沁, 陈练. 产后宫腔内妊娠物残留的诊断和临床处理[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 493-497.
[3] 刘子洋, 崔俭俭, 赵茵. 产科弥散性血管内凝血及其评分系统的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 511-518.
[4] 谢江燕, 王亚菲, 贺芳. 妊娠合并血栓性血小板减少性紫癜2例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 556-563.
[5] 刘莉莉, 贾建茹, 张晶, 周大琼, 刘江雨, 曹振环. 单纯慢性乙型肝炎患者与慢性乙型肝炎合并肝脂肪变患者的临床特征横断面研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 270-277.
[6] 张静, 刘畅, 华成舸. 妊娠期患者口腔诊疗进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(05): 340-344.
[7] 徐敬云, 丁波, 蒋宇慧, 沈杨. 妊娠期单孔腹腔镜手术实施行与思[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 262-266.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[11] 傅斌生, 冯啸, 杨卿, 曾凯宁, 姚嘉, 唐晖, 刘剑戎, 魏绪霞, 易慧敏, 易述红, 陈规划, 杨扬. 脂肪变性供肝在成人劈离式肝移植中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 789-794.
[12] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[13] 伍细蓉, 徐立文, 陈亚琼. 基于LPR和FARI构建肝衰竭患者生存预后模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 675-681.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 黄圣楷, 许斌, 苏健, 孙龙. 海南省2010~2020年乙型肝炎流行趋势的时间序列分析及预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 555-561.
阅读次数
全文


摘要